CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Every investor aspires to see the
stocks in their portfolio deliver substantial returns. Though trading is a game
of probabilities, with both wins and losses, some investors manage to hit the
jackpot.

The following compilation represents a selection of stocks featured on our
website that reached new 52-week high levels during the current week. However,
please note that this list is not comprehensive and does not encompass all the
stocks that achieved this milestone.

Protagonist Therapeutics Inc. (PTGX)

Protagonist is a clinical-stage biopharmaceutical company with multiple assets
having billion-dollar market potential.

The company has a worldwide license and collaboration agreement with Takeda for
investigational drug Rusfertide under development for polycythemia vera and
other blood disorders. A phase III trial evaluating Rusfertide in polycythemia
vera, dubbed VERIFY, is underway, and top-line data for the study's 32-week
primary efficacy endpoint is anticipated by the end of the first quarter of
2025.

Next up is JNJ-2113 (formerly known as PN-235), being developed pursuant to the
license and collaboration agreement between Protagonist and Janssen Biotech
Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. JNJ-2113
is under phase III trials in moderate-to-severe plaque psoriasis and in a phase
IIb trial in moderately to severely active ulcerative colitis.

PTGX was featured on our site on Mar.7, 2023, when it was trading around $16.97.
The stock closed yesterday's trading at $34.02, reflecting an impressive 100%
gain from our published price.

Calliditas Therapeutics AB (publ) (CALT)

Calliditas is a Sweden-based commercial-stage biopharma company developing novel
treatments for orphan indications with significant unmet medical needs.

The company's lead drug is Nefecon, marketed under the brand name Tarpeyo, to
reduce proteinuria in adults with primary immunoglobulin A nephropathy. The
drug, which was granted accelerated approval by the FDA in Dec.2021, received
full approval in Dec.2023.

Tarpeyo is also marketed in EEA, Switzerland and the UK under the brand name
Kinpeygo. In the EU, Kinpeygo was granted conditional marketing authorisation in
July 2022, and awaits the full approval in August of this year.

For the first quarter ended March 31, 2024, net sales of Tarpeyo were $26.8
million compared to $17.8 million in the year-ago quarter. Preliminary net sales
of Tarpeyo for the second quarter of 2024, are estimated to be $25.5 million
compared to $25 million in the second quarter of 2023.

CALT was featured on our site on Mar.13, 2023, when it was trading around
$22.60. The stock closed yesterday's trading at $41.41, and that implies a gain
of 83% from our published price.

Stoke Therapeutics Inc. (STOK)

Stoke is a clinical-stage biotechnology company developing RNA-based medicines.
Its lead drug candidate is STK-001, which is in clinical testing for the
treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

The company is planning to meet with regulatory agencies to discuss its plans
for a randomized, controlled registrational study for STK-001 and an update
related to this is expected in the second half of 2024.

Our site featured STOK on Apr.14, 2023, when its trading price was hovering
around $8.77. Remarkably, the stock closed at $15.21 yesterday, reflecting a 73%
upswing in value from our published price.

Halozyme Therapeutics Inc. (HALO)

Halozyme is a biopharmaceutical company, whose ENHANZE drug delivery technology
is licensed to pharma and biotech companies, including Roche, Takeda, Pfizer,
AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics,
ViiV Healthcare and Chugai Pharmaceutical.

The company commercializes specialty products like adjuvant Hylenex;
testosterone replacement therapies like XYOSTED and TLANDO; and NOCDURNA, which
is indicated for the treatment of nocturia due to nocturnal polyuria in adults
who awaken at least two times per night to urinate. Revenue is also generated
from ENHANZE collaborations and from the sales and/or royalties of its approved
products.

For full year 2024, the company anticipates total revenue of $935 million to
$1,015 million, representing growth of 13% to 22% over 2023, primarily driven by
increases in royalty revenue, collaboration revenue and growth in product sales
from XYOSTED.

Our site featured HALO on July 13, 2023, when its trading price was around
$37.55. The stock closed at $51.44 yesterday, reflecting a decent gain of 37%
from our published price.

PepGen Inc. (PEPG)

PepGen is a clinical-stage biotechnology company developing therapeutics for the
treatment of severe neuromuscular and neurological disorders. The lead drug
candidate is PGN-EDO51, under phase II testing for the treatment of Duchenne
Muscular Dystrophy. Also in the pipeline is PGN-EDODM1, under phase I trial for
Myotonic Dystrophy 1.

The company anticipates reporting preliminary data from the phase I trial of
PGN-EDODM1, dubbed FREEDOM-DM1 in the second half of 2024.

We highlighted PEPG on our site on Oct.12, 2023, when it was trading around
$5.23. The stock closed yesterday's trading at $17.34, marking an impressive
gain of 231% from our published price.

Agios Pharmaceuticals Inc. (AGIO)

Agios Pharma, pioneering therapies for rare diseases, is a commercial-stage
company. Its flagship drug is Mitapivat, approved for the treatment of hemolytic
anemia in adults with pyruvate kinase deficiency in the U.S., EU and Great
Britain, under the brand name Pyrukynd.

Early this month, Agios announced that its phase III study of Mitapivat in
adults with transfusion-dependent alpha- or beta-thalassemia, dubbed ENERGIZE-T,
met the primary endpoint of transfusion reduction response.

AGIO was trading around $21.20 when it was highlighted on our site on Nov.3,
2023. The stock closed yesterday's trading at $47.80, implying a gain of 125%
from our published price.

Vertex Pharmaceuticals Inc. (VRTX)

Vertex Pharma is a global biotechnology company that has approved medicines for
cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia.

For full year 2024, the company expects total product revenue to be in the range
of $10.55 billion to $10.75 billion. The product revenue was $9.87 billion in
2023.

VRTX was featured on our site on Jan.3, 2024, when it was trading around
$412.43, The stock closed yesterday's trading at $485.53, implying a decent gain
of 17% from our published price.

ADMA Biologics Inc. (ADMA)

ADMA Biologics is a commercial biopharmaceutical company developing specialty
plasma-derived products for the prevention and treatment of infectious diseases
in immune compromised and other patients at risk for infection.

When reporting first quarter financial results last month, the company made
significant increases to both top- and bottom-line projections for 2024 and
2025.

The total revenue for full year 2024 is now expected to be more than $355
million, up from its prior guidance of over $330 million. The total revenue was
$258 million in 2023.

Looking ahead to 2025, the total revenue is now projected to be more than $410
million, up from its earlier estimate of over $380 million.

We featured ADMA on our site on Feb.15, 2024, when it was trading around $5.36.
The stock closed yesterday's trading at $10.58, reflecting an impressive 97%
upswing from our published price.

Insmed Inc. (INSM)

Insmed is a revenue-generating global biopharmaceutical company. Its lead drug
Arikayce is indicated for the treatment of Mycobacterium avium complex (MAC)
lung disease in adults who have limited or no alternative treatment options.

For full year 2024, the company expects global Arikayce revenue to be in the
range of $340 million to $360 million. The drug generated revenue of $305.2
million in 2023.

We highlighted INSM on our site on Mar.25, 2024, when it was trading around
$26.52. The stock closed yesterday's trading at $57.17, marking a substantial
115% increase from our published price.

Rezolute Inc. (RZLT)

Rezolute is developing a drug for diabetic macular edema by the name RZ402.

Last month, the company reported positive topline results from its phase II
clinical study of RZ402 in patients with DME who are naïve to or have received
limited anti-vascular growth factor (anti-VEGF) injections.

We featured RZLT on our site on Apr.1, 2024, when it was trading around $2.68.
The stock closed yesterday's trading at $5.59, exhibiting a notable 108% rally
from our published price.

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus is a global messenger RNA medicine company. Its lead product Kostaive,
a self-amplifying mRNA COVID-19 vaccine for primary vaccination and booster for
adults 18 years and older, developed in partnership with CSL, is expected to be
launched in Japan this year. The vaccine was approved by Japan's Ministry of
Health, Labor and Welfare last November.

The company also has two wholly owned mRNA therapeutic candidates in clinical
development - ARCT-032 for Cystic Fibrosis and ARCT-810 for ornithine
transcarbamylase (OTC) deficiency.

New Phase 1b interim data for ARCT-032 will be presented at European Cystic
Fibrosis Conference today.

ARCT was featured on our site on Apr.9, 2024, when it was trading around $30.83.
The stock closed yesterday's trading at $42.60, representing a gain of 38% from
our published price.

Novavax Inc. (NVAX)

Novavax is a global company advancing protein-based vaccines with its Matrix-M
adjuvant. This Covid-vaccine maker signed a licensing deal worth $1.2 billion
with Sanofi last month.

For the first quarter ended Mar.31, 2024, total revenue was $94 million,
compared to $81 million in the same period in 2023.

Novavax is aiming to deliver JN.1 protein-based non-mRNA COVID-19 vaccine this
Fall.

We profiled NVAX on our site on May 13, 2024, when it was trading around $9.69.
Yesterday's closing price of $19.56 implies a 101% appreciation from our
published price.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX